ClinicalTrials.gg
RecruitingNCT07293468BIIRTHUpdated Apr 9, 2026

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

A Phase 2/3 interventional study of Transarterial chemoembolization (TACE) and Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC), sponsored by Tuen Mun Hospital. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Tuen Mun Hospital · Phase 2/3, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Apr 2024, registered Dec 2024).
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 122 studies in Carcinoma, Hepatocellular with a site in Hong Kong — 16 open to participants now, 28 under way, 7 of them phase 3. Carcinoma, Hepatocellular · Hong Kong.

Planned enrollment
54th of 110
106 · median 97
Started
2024
with 5 others
Phase 2/3
2 of 122
1 open now
Primary completion
2034-03
later than 27 of 27 live
Registered
115th of 122
by date

Among the 122 studies in Carcinoma, Hepatocellular with a site in Hong Kong, this one is the 54th largest by planned enrollment of the 110 interventional ones that give a count, is one of 6 that started in 2024, is one of 2 in phase 2/3, reaches primary completion later than 27 of the 27 other live ones, and was the 115th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

16 of the 122 studies in Carcinoma, Hepatocellular with a site in Hong Kong are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Carcinoma, Hepatocellular with a site in Hong Kong, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the safety and efficacy of sequential Transarterial Chemoembolization (TACE) and Stereotactic body radiation therapy (SBRT) versus Y90-radioembolisation (SIRT), followed by systemic therapy in patients with large, locally advanced, unresectable Hepatocellular carcinoma (HCC).

The main question it aims to answer is whether Sequential TACE-SBRT potentially gives longer Progression-free survival (PFS) benefit with similar toxicities as compared with Y90 SIRT.

Participants will be recruited via multidisciplinary meetings (MDTs) with hepatobiliary surgeons, medical hepatologists and radiologists with consistent, strict considerations on eligibility and treatment alternatives. Eligible patients will be randomized in 1:1 ratio to received one of the two treatment arms.

Read the detailed description

Hepatocellular carcinoma (HCC) represents a major global health threat, ranking sixth in worldwide cancer incidence and third in cancer mortalities. Southeast Asia remains endemic, with liver cancer ranking fifth and third in local cancer incidence and mortalities respectively according to the Hong Kong Cancer Registry. While resection, radiofrequency ablation (RFA) and liver transplantation represents chances of cure, only 30% of patients are eligible for curative local intervention upon presentation. Large, locally advanced HCCs represent a distinct population of aggressive clinical courses conferring poor prognoses and are often rapidly symptomatic, with limited treatment options and represent true unmet clinical needs.

1.1 Current Landscape of Locoregional Therapies for Locally Advanced HCC

A substantial population of locally advanced HCC patients die of intra-hepatic treatment failures. Intensifying local treatment strategies has been suggested to improve survival outcomes, hence optimizing locoregional therapy is of paramount importance. Transarterial chemoembolization (TACE) remains the most widely adopted local treatment modality in unresectable HCCs. Growing evidence, however, has demonstrated limited efficacy among large tumours, with reported low response rates of roughly 30% among large (≥5cm) or multinodular HCCs and poor 2-year overall survival of 0% for tumour sizes ≥8 cm.

On the other hand, radiotherapy techniques have evolved, with stereotactic body radiotherapy (SBRT) and selective internal radiotherapy (SIRT) gaining recognition in the treatment of large unresectable HCCs. SIRT has been suggested to be as effective as sorafenib in HCC patients with liver-only involvement with more favourable tumour response and side effect profile. Lately, the American Society for Radiation Oncology (ASTRO) Clinical Practice Guideline on External Beam Radiotherapy (EBRT) for Primary Liver Cancers 2021 recommended EBRT as a potential first-line therapy option in liver-confined, incurable HCCs alongside with catheter-based therapies including TACE and SIRT.

While Y90 SIRT is considered the Hospital Authority's standard in HCC patients with tumours (i) ≥8cm, or (ii) presence of portal vein invasion, or (iii) as a bridge therapy to liver transplantation, there is currently no prospective, head-to-head comparison on the choice of locoregional therapy, and growing evidence urges optimization and standardization of treatment algorithms for locally advanced, unresectable tumours.

1.1.1 SIRT Radioembolization with 90yttrium (Y90)-tagged glass or resin microspheres has been an internationally recognized and widely-practiced local treatment modality among large, unresectable HCCs. Salem et al reported comparable outcomes to TACE in terms of response rate (42%) and time-to-progression (7.9 months) for a sample of 291 patients with median tumour sizes of 7 cm with acceptable toxicities. As Hospital Authority's standard indication, Y90 SIRT is considered in HCC patients with tumours (i) ≥8cm, or (ii) presence of portal vein invasion, or (iii) as a bridge therapy to liver transplantation.

However, price and accessibility concerns have limited its application, especially among pandemic areas and/or developing countries. In addition, more vigorous screening is required to meet the eligibility criteria for SIRT. In particular, a pre-treatment Technetium-99m (99mTc) macroaggregated albumin (MAA) scan is required as initial screening, in which only patients without significant lung shunting of hepatic artery blood flow are considered eligible. While HCC patients were found to have higher median lung shunt fraction (LSF) than other metastatic liver tumours, as high as 21.4% were ineligible for Y90 due to an exceedingly high LSF.

1.1.2 TACE with SBRT SBRT liver has emerged as a promising local therapy in patients with locally advanced HCCs. While TACE alone might be suboptimal in treating large, unresectable HCCs, meta-analyses concluded an improvement in OS with combination TACE and EBRT as compared to TACE alone. Furthermore, a retrospective study of patients with unresectable HCCs and a median tumour size of 8.5cm (5.1-21cm) demonstrated a significantly better 5-year OS rate of 46.9% vs 32.9% among those who received combination TACE and SBRT versus SBRT alone.

The American Society for Radiation Oncology (ASTRO) clinical practice guideline on EBRT for primary liver cancers conditionally recommended the use of EBRT in patients with liver-confined, multifocal and/or unresectable HCCs, with or without macrovascular invasion, either alone or sequenced with other catheter-based therapies. The relatively high accessibility, less expensive RT and TACE interventional radiology facilities has represented a highly attractive treatment option.

Prior local work has been done. A substantially enhanced anti-tumour response and survival benefits with similar toxicities by means of sequential single-course of TACE followed by SBRT as compared with the TACE alone group by propensity score matched analysis was reported. Subsequently, a published 2020 study evaluating 55 consecutive patients with large (≥10 cm) HCCs of median tumour sizes 15.3cm (range, 10.0-25.7cm) receiving sequential TACE and hypofractionated image-guided radiotherapy (HIGRT) at Tuen Mun Hospital during 2007-2017 with a 1-year local in-field progression-free survival (PFS) rate of 57.4% (95% CI = 40.8%-74.0%). Notably, 27% of treatment responders achieved remarkable tumour downstaging and underwent subsequent curative resection, achieving a significantly prolonged OS of 41.2months (95% CI, 19.1-63.2 months) as compared to those without surgery. Such results are also in line with the Hong Kong consensus statements on unresectable HCC 2021 guidelines affirming the role of combination TACE and SBRT.

1.1.3 Immune Checkpoint Inhibitors (ICI) While systemic therapy is also considered a standard therapeutic option in locally advanced, unresectable HCCs, response rates were modest even in the post-immunotherapy era, ranging from 5-40%. Atezolizumab, a programmed death ligand 1 (PD-L1) inhibitor, in combination with bevacizumab, a monoclonal antibody against the vascular endothelial growth factor (VEGF), is the preferred first-line treatment option since the establishment of IMbrave150 trial. The response rate at 27.3% (95% CI, 7.4-18.0%), albeit the presence of survival benefits, urges needs for further improvement.

1.2 Emerging Combination of Locoregional and Systemic Therapy and Potential Surgical Conversion in Local Advanced HCCs

Evolving evidence suggests upfront liver-directed therapy application followed by systemic therapy combination could achieve successful tumour downstaging in locally advanced HCCs leading to curative surgeries and improved survival. The randomized, multicentre, phase 3 NRG/RTOG 1112 trial reported the addition of SBRT to sorafenib has improved OS, PFS and TTP in advanced HCC patients versus Sorafenib alone, with no significant increase in adverse events. Another recent prospective single arm, single centre, phase 2 NASIR-HCC study demonstrated rates of surgical conversion (9.5%), partial response (PR) (16.7%) and OR (41.5%; 95% CI: 26.3-57.9%), as well as median time to progression (mTTP) of 8.8months (95% CI: 7.0-10.5months) and mOS of 20.9months (95% CI: 17.7-24.1months) in 42patients with HCCs exceeding 5cm or multiple beyond the up-to-seven criteria treated with SIRT followed by nivolumab combination therapy.

Moreover, local research is emerging. The published START-FIT study in Lancet Gastroenterology and Hepatology was a prospective single arm, multi-centre phase 2 trial demonstrating initial success of the novel, sequential TACE-SBRT-immunotherapy (avelumab) approach. Promising rates of conversion (55%), complete response (CR) (42%) and objective response (OR) (66.7%; 95% CI: 48.2-82.0%), as well as favourable mPFS of 20.7months (95% CI: 14.6-26.8months) and median overall survival (mOS) of 30.3months (95% CI: 22.7-37.8months) were achieved in 33 patients with locally advanced, upfront unresectable HCCs of median sizes 15.1cm (range: 5.3-31.1cm). Toxicity profile was also favourable, hereby demonstrating the safety and efficacy of our combination TACE-SBRT and immunotherapy treatment. Since then, two propensity score matching analyses, one of which was in Liver Cancer, demonstrated a significantly improved OS rates of SBRT-immunotherapy as compared to TACE alone (2-year OS 80.4% vs. 8.3%), and SBRT alone (3-year OS 62.9% vs. 43.4%) respectively.

While sequential local-systemic therapy is expected to be synergistic, direct comparison on the different types of local therapy backbone is lacking. Determining the optimal loco-systemic treatment strategy is therefore integral to achieve potential surgical conversion and unlock major survival benefits.

With results of combination TACE and SBRT being numerically favourable as compared to that of SIRT, a comparison of sequential TACE-SBRT versus Y90 SIRT would therefore be the next logical investigation approach. We aim at conducting a prospective trial with head-to-head comparison on combinational TACE-SBRT versus Y90 SIRT as standard locoregional therapy, together with combination immunotherapy treatment among locally advanced HCCs.

This project carries substantial impact on HCC management via:

(a) establishing the role of locoregional therapy in the post-immunotherapy era, (b) shedding light on local and international guidelines of incorporating locoregional therapy to first-line treatment in locally advanced HCC patients, and (c) potentially unlocking major, durable survival benefits through the synergistic effects of optimal local-systemic therapy combination among patients with locally advanced HCCs whom prognosis is guarded and treatment option is limited.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • TACE
  • SBRT
  • Y90
  • SIRT
  • immunotherapy
  • combination therapy
  • locally advanced
  • unresectable HCC
  • RCT
  • liver
  • hepatocellular carcinoma
  • stereotactic body radiotherapy
  • transarterial chemoembolization
  • radioembolization
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with HCC either by histology or by the American Association for the Study of Liver Diseases Criteria (AASLD) 2018
  • Patients age 18-80 years of age with HCCs deemed unresectable at the Multidisciplinary Team Meetings (MDTs) because of the following:
  • R0 resection not feasible e.g. unfavourable tumour location
  • Remnant liver volume \<30% in non-cirrhotic patients or 40% in cirrhotic patients
  • Indocyanine green test >15%
  • Patients with Barcelona Clinic Liver Cancer (BCLC) stage B2-4 (unresectable group) or C
  • Tumour sizes of ≥5cm, of which ≥1 is a as defined by the criteria
  • Subjects aged 18-80 years of age
  • performance status of 0-1
  • Predicted should be of ≥ 3 months
  • (CP) score of A5-B7
  • Adequate organ and marrow functions, as listed below:
  • ≥9 g/dL
  • ≥1,500/uL
  • count ≥100,000/L
  • Total ≤2.0 x (ULN)
  • Albumin ≥2.8 g/dL
  • ≤3 x ULN
  • ≤1.6
  • Calculated () ≥45 mL/minute as determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine clearance
  • Liver volume minus intrahepatic gross tumour volume (GTV) with >700cc
  • Patients with concomitant infection (defined as having HBsAg positive and/or detectable HBV DNA level) must be treated with antiviral therapy (per local institutional practice) to ensure adequate viral suppression (defined as HBV DNA \<2,000 IU/mL) prior to enrolment, throughout study duration and continue for at least 6 months following the last dose of local-systemic therapy
  • provided
  • Females of or non-sterilized male who are sexually active must use a highly effective method of
  • Females of childbearing potential must have negative serum or urine pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Prior invasive within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, lobular or ductal carcinoma in situ of the breast that has been surgically cured
  • Presence of any extra-hepatic
  • Presence of main portal vein (PV) or inferior vena cava (IVC) involvement
  • Presence of active, uncontrolled varices
  • Presence of active, severe comorbidities including uncontrolled cardiovascular or cerebrovascular diseases or recent events within 6months prior to treatment
  • Received prior non-curative locoregional (including TACE, RT to liver, SIRT) or systemic therapy received for HCC\
  • Prior treatment with any anti-programmed cell death protein-1 (), PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2) agent, or an antibody targeting other immune-regulatory receptor(s) or mechanism(s)
  • Use of chronic systemic or any other medication within 14days prior to treatment initiation, except:
  • Intranasal, inhaled, topical steroids, or local steroid injection;
  • Systemic corticosteroids at physiologic doses ≤10mg/day of prednisone or equivalent;
  • Steroids as premedication for reactions
  • Active or documented or inflammatory disorders within 2years, except diabetes type I, vitiligo, psoriasis, or hypo-/hyperthyroid diseases not requiring immunosuppressant(s)
  • Known history of a positive test, primary/acquired immunodeficiency syndrome, or solid organ transplantation
  • Receipt of live, attenuated vaccine within 28 days prior to study treatment
  • Severe hypersensitivity reaction to another monoclonal antibody
  • Presence of any to TACE not otherwise listed: cisplatin allergy
  • Presence of any contraindication to SBRT not otherwise listed:
  • Maximal size of any one HCC >25 cm
  • Direct tumour extension into gastrointestinal structures (stomach, duodenum, remaining small or large bowel)
  • Presence of any contraindication to SIRT not otherwise listed:
  • Pre-treatment 99mTc-MAA scan >20% lung shunting of hepatic artery blood flow, or a demonstration of radiation exposure to the lungs potentially >25Gy
  • Pre-treatment hepatic angiogram showing potential Y90 microspheres deposition in the gastrointestinal tract or any other organ(s) which is not correctable by catheter embolization techniques.
  • Pregnant or lactating females
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    TACE-SBRT arm

    Combination TACE and SBRT followed by immunotherapy

    Procedure: Transarterial chemoembolization (TACE) · Radiation: Stereotactic Body Radiation Therapy (SBRT) · Drug: Atezolizumab & Bevacizumab

  • Active comparator
    Y90 SIRT arm

    Combination Y90 SIRT followed by immunotherapy

    Radiation: SIRT Yttrium-90 · Drug: Atezolizumab & Bevacizumab

Interventions

  • ProcedureTransarterial chemoembolization (TACE)

    One dose of TACE would be performed as per standardized procedure at 21-35 days preceding SBRT. Celiac and superior mesenteric arterial and porto-venogram would be performed to exclude main portal vein occlusion and to delineate the size(s) and number(s) of tumour nodule(s). Supra-selective cannulation of the supplying tumour artery would follow. The 1:1 lipiodol-cisplatin emulsion prepared by pumping would be slowly injected under fluoroscopic guidance according to the tumour size and arterial blood flow.

  • RadiationStereotactic Body Radiation Therapy (SBRT)

    Patients are immobilized with customized device and abdominal compression or active breathing control. Four-dimensional computed tomography (4D-CT) was phase-sorted into 10 image-sets. A radiation dose of 27.5-50.0 Gy in five fractions, delivered in alternate days, is allowed. The prescription dose is individualized based on normal tissue constraints. This should be based on delivering a maximal tumoricidal dose while respecting the tolerance dose of neighbouring organs-at-risk. SBRT is delivered by dynamic conformal arc therapy, intensity-modulated RT, or volumetric modulated arc RT.

  • RadiationSIRT Yttrium-90

    Patients undergo intrahepatic arterial Y90-radioembolisation (TheraSphere glass microspheres; MDS Nordion, Ottawa, Canada or SIR-Spheres, Sirtex Medical Pty Limited; St. Leonards, NSW, Australia). The administered activity of Y90-glass microspheres was determined by the nuclear medicine physician, medical physicist, radiologist and clinical oncologist using the artery-specific partition model within the limits of radiation safety, taking into account treatment variables including patient's body surface area, tumour-to-normal liver ratio, and liver tumour size. Where possible, personalized dosimetry using the partition model was the default methodology to facilitate selective administration of Y90-radioembolisation avoiding toxicities to the normal liver parenchyma.

  • DrugAtezolizumab & Bevacizumab

    Drug pages: AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will start Atezolizumab-bevacizumab 14days upon completion of SBRT or SIRT. Atezolizumab, if given, is administered via IV infusion at a fixed dose of 1200mg, together with Bevacizumab (start 28days after SBRT/SIRT) via IV infusion at a fixed dose of 15mg/kg, on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator, or after curative surgical intervention is performed with no evidence of residual disease. Patients who transiently or permanently discontinued either atezolizumab or bevacizumab due to an adverse event are allowed to continue with single-agent therapy provided there is ongoing clinical benefit as determined by the investigator.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Time frame: defined as the period from the date of starting TACE or Y90-radioembolisation to the time of local, in-field disease progression, or the time of patient death, whichever occurring first; up to 10 years

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: defined as the period from the date of starting TACE or Y90-radioembolisation to the date of patient death; up to 10 years

  2. Objective response rate (ORR) per mRECIST criteria

    treatment response measurement

    Time frame: The percentage of patients in each study group achieving a partial response or complete response to intervention arm, from start of TACE or SIRT to date of progression or death; up to 10 years

  3. Local Control (LC)

    Defined as the absence of progressive disease within the PTV per mRECIST, i.e. the sum of Clinical Remission (CR), Partial Response (PR) and Stable Disease (SD)

    Time frame: From start of TACE or SIRT to local (target lesion) progression or death, whichever occurs first; up to 10 years

  4. Surgical conversion rate

    Defined as the percentage of patients amendable to curative surgical interventions or transplantation after successful tumour(s) down-sizing by intervention treatment

    Time frame: From treatment to disease progression or death, up to 10 years

  5. Pathological response

    Defined as the percentage of surface with non-viable cancer cells (represented by necrosis or fibrosis) in relation to the total tumour area = 100% - viable cancer cells (%).

    Time frame: From treatment completion to disease progression or death; up to 10 years

  6. Factors independently associated with survival outcomes of treated patients

    Baseline characteristics are to be recorded and analyzed using univariate and multivariate analyses to identify factors independently associated with survival outcomes of treated patients

    Time frame: From start of treatment to progression or death of treated patients; up to 10 years

  7. Toxicities measurement

    Incidence, nature, and severity of adverse events graded according to the United States National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0)

    Time frame: From start of treatment to progression or death of treated patients; up to 10 years

  8. Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire

    To assess patient-reported quality of life by means of serial FACT-Hep validated questionnaire; the score ranges from 0-180, with a higher score representing a better quality of life.

    Time frame: From pre-treatment baseline to disease progression or death; up to 10 years

  9. European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) Questionnaire

    To assess patient-reported quality of life by means of serial European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) validated questionnaire. The EORTC QLQ-C30 scale score ranges from 0 to 100. A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptomatology.

    Time frame: From pre-treatment baseline to disease progression or death; up to 10 years

  10. Radiomics

    To develop a radiomics model with robust features for survival prediction of liver cancer patient after SIRT or SBRT; through analysis of diagnostic and progress CT imaging features in study participants

    Time frame: From pre-treatment baseline imaging to the last imaging before the death of treated patients; for up to 10 years

  11. Predictive Biomarkers

    Potential, predictive blood biomarkers, including peripheral mononuclear cells (PBMC), exosomal PD-L1 are serially measured during individual patients' entire treatment course

    Time frame: From pre-treatment baseline blood tests to the last before the death of treated patients; for up to 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wong N, Chiang C, Ho C, Yip W, Yeung C, Chan M, et al. Prognostic Factors and Survival in Advanced Large Hepatocellular Carcinomas Treated with Combined Transarterial Chemoembolisation and Hypofractionated Image-guided Radiotherapy. Hong Kong Journal of Radiology. 2020 Sep 25;23(3):198-207.
  • Chiang CL, Chan KSK, Chiu KWH, Lee FAS, Chen W, Wong NSM, Ho RLM, Lee VWY, Man K, Kong FMS, Chan ACY. Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma. JAMA Oncol. 2024 Nov 1;10(11):1548-1553. doi: 10.1001/jamaoncol.2024.4085. PubMed 39325464 ↗
  • Chiang CL, Lee FAS, Chan KSK, Lee VWY, Chiu KWH, Ho RLM, Fong JKS, Wong NSM, Yip WWL, Yeung CSY, Lau VWH, Man K, Kong FMS, Chan ACY. Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2023 Oct 1;13(3):265-276. doi: 10.1159/000533425. eCollection 2024 Jun. PubMed 38756147 ↗
  • Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):169-178. doi: 10.1016/S2468-1253(22)00339-9. Epub 2022 Dec 15. PubMed 36529152 ↗
  • de la Torre-Alaez M, Matilla A, Varela M, Inarrairaegui M, Reig M, Lledo JL, Arenas JI, Lorente S, Testillano M, Marquez L, Da Fonseca L, Argemi J, Gomez-Martin C, Rodriguez-Fraile M, Bilbao JI, Sangro B. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J Immunother Cancer. 2022 Nov;10(11):e005457. doi: 10.1136/jitc-2022-005457. PubMed 36450386 ↗
  • Dawson LA, Winter K, Knox J, Zhu AX, Krishnan S, Guha C, et al. NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiat Oncol. 2022 Dec;114(5):1057.
  • Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, Hallemeier CL, Koay EJ, Lasley F, Meyer J, Owen D, Pursley J, Schaub SK, Smith G, Venepalli NK, Zibari G, Cardenes H. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2022 Jan-Feb;12(1):28-51. doi: 10.1016/j.prro.2021.09.004. Epub 2021 Oct 21. PubMed 34688956 ↗
  • Wong SS, Wong WH, Ngar DY, Ma VW, Cheung C, Lee FA. NTWC Guideline for Transarterial Radioembolization using Yttrium-90 Microspheres (Y90-TARE). Hong Kong; 2020 Sep. (1).
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Mar 2034, 119 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 19, 2025
StartActual
Apr 1, 2024
Primary completionEst.
Mar 31, 2034
CompletionEst.
Dec 31, 2034
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07293468
Lead sponsor
Tuen Mun Hospital
Collaborators
Queen Mary Hospital, Hong Kong, The University of Hong Kong, The University of Hong Kong-Shenzhen Hospital
Responsible party
Wong Sean Man Natalie (Principal Investigator, Tuen Mun Hospital) — Principal investigator
First posted
Dec 19, 2025
Start date
Apr 1, 2024
Primary completion
Mar 31, 2034 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Apr 9, 2026

Study contacts

Sean Man Natalie WONG
Contact
wsm011@ha.org.hk
852-24685088
Man TONG
Contact
tm326@ha.org.hk
852-24685086

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion